8 results
The primary objective of the study is to demonstrate the antitumor activity of LDK378.
In a small pilot study to investigate possible occurence of blood chemistry deviations and / or a tamponade after the application of ACF-Matrix haemostat in the (L)IMA bed.
Primary: To assess the steady-state PK of 450 mg or 600 mg ceritinib taken daily with a low-fat meal as compared with that of 750 mg ceritinib taken daily in the fasted state in patients with metastatic ALK-positive NSCLC.Secondary: Overall response…
The primary objective is to evaluate the antitumor activity of ceritinib in patients with ALK-positive NSCLC metastatic to the brain and/or toleptomeninges based on whole body overall response rate (ORR), defined as the proportion of patients with a…
Primary: 1. To determine the MTD and/or RDE of the combination ceritinib and nivolumab. 2. To assess the preliminary antitumor activity of the combination.Secondary: 1: To assess the safety profile of the ceritinib and nivolumab combination. 2: To…
The primary objective is to compare the antitumor activity of LDK378 versus reference chemotherapy.The key secondary objective is to compare Overall Survival (OS) in patients treated with LDK378 versus reference chemotherapy (pemetrexed or docetaxel…
The main objective is to evaluate the average time span within which *time of onset* and *time of offset* occurs in patients with overactive bladder syndrome or non-obstructive urinary retention who respond to SNM.
The primary objective is to compare the antitumor activity of LDK378 versus reference chemotherapy